Taysha Gene Therapies, Inc. (TSHA)
Largest Insider Buys in Sector
TSHA Stock Price History Chart
TSHA Stock Performance
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, …
Insider Activity of Taysha Gene Therapies, Inc.
Over the last 12 months, insiders at Taysha Gene Therapies, Inc. have bought $3M and sold $0 worth of Taysha Gene Therapies, Inc. stock.
On average, over the past 5 years, insiders at Taysha Gene Therapies, Inc. have bought $6.24M and sold $975,279 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Manning Paul B (10 percent owner) — $15M.
The last purchase of 1,333,333 shares for transaction amount of $3M was made by Manning Paul B (10 percent owner) on 2024‑06‑27.
List of Insider Buy and Sell Transactions, Taysha Gene Therapies, Inc.
| 2024-06-27 | 10 percent owner | 1.33M 0.7863% | $2.25 | $3M | 0.00% | |||
| 2023-11-17 | 10 percent owner | 100,000 0.0519% | $1.63 | $163,000 | +28.74% | |||
| 2023-08-24 | Sale | Chief Financial Officer | 33,000 0.0537% | $2.33 | $76,890 | +0.43% | ||
| 2023-08-16 | 10 percent owner | 16.47M 11.9647% | $0.90 | $14.82M | +21.50% | |||
| 2023-08-16 | Chief Executive Officer | 444,444 0.3229% | $0.90 | $400,000 | +21.50% | |||
| 2023-08-16 | director | 777,778 0.5651% | $0.90 | $700,000 | +21.50% | |||
| 2023-08-16 | director | 111,111 0.0807% | $0.90 | $100,000 | +21.50% | |||
| 2023-07-13 | Sale | 10 percent owner | 5,344 0.0084% | $0.70 | $3,741 | +232.86% | ||
| 2023-07-12 | Sale | 10 percent owner | 80,528 0.1263% | $0.71 | $57,030 | +224.23% | ||
| 2023-06-23 | Sale | 10 percent owner | 18,100 0.0305% | $0.70 | $12,735 | +242.42% | ||
| 2023-06-22 | Sale | 10 percent owner | 10,508 0.0163% | $0.70 | $7,384 | +214.94% | ||
| 2023-06-21 | Sale | 10 percent owner | 138,962 0.2204% | $0.70 | $97,635 | +221.43% | ||
| 2023-06-20 | Sale | 10 percent owner | 295,653 0.4778% | $0.71 | $210,209 | +223.74% | ||
| 2023-05-16 | President and Head of R&D | 5,000 0.0078% | $0.68 | $3,400 | +173.12% | |||
| 2022-10-31 | director | 1.5M 3.9684% | $2.00 | $3M | -34.88% | |||
| 2022-08-23 | Sale | Chief Financial Officer | 3,325 0.0081% | $3.47 | $11,538 | -67.72% | ||
| 2022-08-18 | Sale | Chief Financial Officer | 11,482 0.0271% | $3.75 | $43,058 | -71.13% | ||
| 2022-07-05 | Sale | CMO and Head of R&D | 3,905 0.0095% | $3.51 | $13,707 | -48.86% | ||
| 2022-06-29 | Sale | CMO and Head of R&D | 12,324 0.0304% | $3.81 | $46,954 | -51.95% | ||
| 2022-02-03 | 76,602 0.2022% | $7.84 | $600,560 | -59.00% |
Insider Historical Profitability
| Manning Paul B | 10 percent owner | 1333333 0.6506% | $2.01 | 9 | 0 | <0.0001% |
| Session R.A. II | 10 percent owner | 8871747 4.3289% | $2.01 | 1 | 6 | <0.0001% |
| Nolan Sean P. | Chief Executive Officer | 1535545 0.7493% | $2.01 | 2 | 0 | <0.0001% |
| Stalfort John A III | director | 999381 0.4876% | $2.01 | 1 | 0 | |
| Donenberg Phillip B. | director | 114111 0.0557% | $2.01 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $57.72M | 9.99 | 20.11M | -10.38% | -$6.68M | <0.01 | |
| Avoro Capital Advisors Llc | $53.53M | 9.26 | 18.65M | +328.19% | +$41.03M | 0.64 | |
| RTW Investments, LP | $53.36M | 9.23 | 18.59M | +10.06% | +$4.88M | 0.8 | |
| RA Capital Management, L.P. | $31.2M | 5.4 | 10.87M | -41.14% | -$21.81M | 0.03 | |
| Vr Adviser Llc | $25.83M | 4.47 | 9M | -13.57% | -$4.05M | 1.26 |